ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells $39,080.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the business’s stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $78.16, for a total transaction of $39,080.00. Following the sale, the vice president directly owned 78,390 shares in the company, valued at $6,126,962.40. This trade represents a 0.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Monday, April 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $77.95, for a total transaction of $38,975.00.
• On Friday, March 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $72.62, for a total transaction of $36,310.00.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock traded up $1.38 during trading on Wednesday, hitting $80.88. 308,836 shares of the stock were exchanged, compared to its average volume of 412,504. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of 20.48 and a beta of 0.46. The company has a fifty day moving average price of $77.08 and a 200-day moving average price of $80.70. ANI Pharmaceuticals, Inc. has a 1-year low of $56.71 and a 1-year high of $99.50. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.77. The company had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. ANI Pharmaceuticals’s revenue for the quarter was up 20.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts predict that ANI Pharmaceuticals, Inc. will post 7.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Hantz Financial Services Inc. grew its stake in ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after buying an additional 237 shares during the last quarter. KBC Group NV acquired a new position in ANI Pharmaceuticals in the 1st quarter valued at about $28,000. Advisors Asset Management Inc. acquired a new position in ANI Pharmaceuticals in the 1st quarter valued at about $28,000. Kemnay Advisory Services Inc. acquired a new position in ANI Pharmaceuticals in the 4th quarter valued at about $48,000. Finally, State of Wyoming acquired a new position in ANI Pharmaceuticals in the 2nd quarter valued at about $50,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

ANIP has been the topic of several recent analyst reports. Guggenheim boosted their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Zacks Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.